Rituximab Plus Bendamustine Proves Promising in Young Patients With MCL
May 5th 2022The combination of bendamustine and rituximab plus autologous stem cell transplantation and maintenance rituximab was shown to be an effective first-line treatment with comparable outcomes to R-CHOP/R-DHAP plus ASCT and observation in young patients with transplant-eligible mantle cell lymphoma.
Read More
The Future of Frontline CLL Treatment Hinges on Chemotherapy-Free Approaches
May 3rd 2022Anthony Mato, MD, MSCE, discusses current data surrounding BTK inhibitors in chronic lymphocytic leukemia, the benefits of targeted therapies in this population, ways to begin addressing unmet needs, and the importance of improved clinical trial designs for varying patient populations.
Read More
Administration of RP1 Through Intratumoral Injection Offers Unique Advantages in Melanoma Treatment
April 26th 2022Oncolytic immunotherapy with talimogene laherparepvec and vusolimogene oderparepvec has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration.
Read More
Systemic Advances Shine, But Multidisciplinary Approaches Remain at Core of Skin Cancer Treatment
April 19th 2022Jason Luke, MD, FACP, reviews key points from each presentation from an Institutional Perspectives in Cancer webinar on melanoma and provides perspective on the practice-changing benefits of therapies moving into earlier lines of treatment.
Read More
Frontline Therapy Advances Are Current Focus in SCLC and NSCLC
April 18th 2022Lung cancer management methods are rapidly evolving to encompass immunotherapy in the frontline setting and approved second-line options with tyrosine kinase inhibitors and monoclonal antibodies in non–small cell lung cancer, as well as treatment advances in first- and second-line small cell lung cancer.
Read More
Lung Cancer Management Methods Expand to Encompass Multiple Treatment Perspectives
April 14th 2022New treatment methods in patients with small cell lung cancer and non–small cell lung cancer are on the horizon, with the introduction of combination immunotherapy, biomarker assays, and supportive oncology programs for patients and care partners.
Read More
Recent FDA Approvals Signal Revolution in HER2+ Breast Cancer Treatment
April 11th 2022Mridula George, MD, discusses the variety of innovative HER2-positive breast cancer treatment options that have recently been approved or are undergoing investigation in clinical trials to broaden the standards of care for patients in this subgroup.
Read More